Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

248
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
248
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

354
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
354
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

488
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
488

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations Between Admission C-Reactive Protein and In-Hospital Mortality Amongst Patients with Cardiogenic Shock.

European heart journal. Acute cardiovascular care·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock.

Journal of intensive care medicine·2026
Same author

Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk.

JCO oncology practice·2026
Same author

Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN).

Circulation. Heart failure·2026
Same author

Sex, Race and Ethnicity, and Rurality Disparities in Cardiovascular Death Among Adults With Early-Onset Colorectal Cancer: A Retrospective Cohort Analysis.

Journal of the American Heart Association·2026
Same journal

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank.

Journal of the American Heart Association·2026
Same journal

Sex-Specific Association Between Socioeconomic Status and Stroke Mortality.

Journal of the American Heart Association·2026
Same journal

Social Determinants of Health and Cardiovascular Disease-Related Outcome Disparities Among Breast Cancer Survivors: A Systematic Review.

Journal of the American Heart Association·2026
Same journal

Graded Associations Between Left Ventricular Ejection Fraction Improvement and Cardiorenal Outcomes in Heart Failure With Improved Ejection Fraction.

Journal of the American Heart Association·2026
Same journal

Early Multimodal Motor Training After Stroke Promotes Motor Recovery and Whole-Brain Structural Remodeling.

Journal of the American Heart Association·2026
Same journal

EAT-Lancet Diet, Plasma Metabolites, and Risk of Peripheral Artery Disease: A Prospective Cohort Study.

Journal of the American Heart Association·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Myocarditis-Associated Cardiogenic Shock: A Nationwide Multicenter Study.

Talal El Zarif1, Alexander P Ambrosini1,2, Andi Shahu2

  • 1Department of Internal Medicine Yale School of Medicine New Haven CT.

Journal of the American Heart Association
|November 12, 2025
PubMed
Summary
This summary is machine-generated.

Myocarditis-associated cardiogenic shock is rare but affects younger patients requiring intensive care. This condition is linked to a significantly higher adjusted in-hospital mortality rate.

Keywords:
cardiogenic shockin‐hospital deathleft ventricular assist devicemechanical circulatory supportmyocarditisvasoactive medications

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.7K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K

Related Experiment Videos

Last Updated: Jan 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.7K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Immunology

Background:

  • Limited data exists on managing myocarditis-associated cardiogenic shock.
  • Myocarditis-associated cardiogenic shock presents unique clinical challenges.

Purpose of the Study:

  • To assess the clinical outcomes of patients experiencing cardiogenic shock due to myocarditis.
  • To compare the characteristics and mortality rates of patients with and without myocarditis-associated cardiogenic shock.

Main Methods:

  • Retrospective analysis of the Vizient Clinical Data Base (2015-2023).
  • Stratification of cardiogenic shock patients (≥18 years) by myocarditis status.
  • Augmented inverse probability weighting used to assess in-hospital mortality, controlling for confounders.

Main Results:

  • 0.5% of cardiogenic shock patients had myocarditis (n=2925).
  • Myocarditis patients were younger, more often female, and had different comorbidity profiles.
  • Myocarditis-associated cardiogenic shock patients required more intensive therapies and had a higher adjusted in-hospital mortality (+9.8%).

Conclusions:

  • Myocarditis-associated cardiogenic shock is an uncommon but severe condition.
  • This patient group exhibits a higher adjusted in-hospital mortality rate.
  • Further research into specific therapies for myocarditis-associated cardiogenic shock is essential.